# A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

> **NCT02944383** · PHASE2 · COMPLETED · sponsor: **NeuroBo Pharmaceuticals Inc.** · enrollment: 91 (actual)

## Conditions studied

- Severe Hypertriglyceridemia
- Mixed Dyslipidaemia

## Interventions

- **DRUG:** Gemcabene
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02944383
- **Lead sponsor:** NeuroBo Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2018-01-11
- **Final completion:** 2018-05-09
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02944383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02944383, "A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02944383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*